Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)

• Status: Unknown status
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring the production of Interferon range pre and posttreatment, to evaluate this way the result of the treatment on the immune response

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Salud Publica, Mexico
• Collaborators: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; Instituto Nacional de Enfermedades Respiratorias
• Treatments: Isoniazid

Criteria

Inclusion Criteria:

• Accept to participate. Informed consent.

• Human Immunodeficiency Virus positive test, documented by Western Blot

• Have not received treatment for latent tuberculosis

• Have not been diagnosed pulmonary tuberculosis (Tbp)

• Normal two chest X-rays, Postern-anterior and left lateral.

Exclusion Criteria:

• Active tuberculosis

• Previous diagnosis of tuberculosis

• Antecedent of treatment for active o latent tuberculosis

• Contact with TB patient harboring Multidrug resistance or isoniazid resistant isolates of Mycobacterium tuberculosis.

• Abnormal liver enzyme levels

• Hemoglobin below 8 gr/dl

• Allergy or intolerance to isoniazid

• Peripheral neuropathy

• Ingestion of drugs interacting with isoniazid